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Imprinting disorders (IDs) are a group of eight rare but probably underdiagnosed congenital diseases affecting
growth, development and metabolism. They are caused by similar molecular changes affecting regulation, dosage
or the genomic sequence of imprinted genes. Each ID is characterised by specific clinical features, and, as each
appeared to be associated with specific imprinting defects, they have been widely regarded as separate entities.
However, they share clinical characteristics and can show overlapping molecular alterations. Nevertheless, IDs are
usually studied separately despite their common underlying (epi)genetic aetiologies, and their basic pathogenesis
and long-term clinical consequences remain largely unknown. Efforts to elucidate the aetiology of IDs are currently
fragmented across Europe, and standardisation of diagnostic and clinical management is lacking. The new
consortium EUCID.net (European network of congenital imprinting disorders) now aims to promote better
clinical care and scientific investigation of imprinting disorders by establishing a concerted multidisciplinary
alliance of clinicians, researchers, patients and families. By encompassing all IDs and establishing a wide
ranging and collaborative network, EUCID.net brings together a wide variety of expertise and interests to
engender new collaborations and initiatives.
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Introduction
Imprinting disorders (IDs) are a group of eight rare
congenital diseases affecting growth, development and
metabolism with a lifelong impact on patients’ quality
of life. They are caused by changes in gene regulation
(‘epigenetic mutation’), gene dosage and - rarely - in
gene or genomic sequences (‘genetic mutation’) (Figure 1).
The term genomic imprinting describes the expression of
specific genes in a parent-of-origin-specific manner - that
is, they are expressed only from the maternal or from the
paternal gene copy, but not biparentally (for review: [1]).
The underlying epigenetic basis does not involve the DNA
sequence itself, but regulatory mechanisms that ensure* Correspondence: teggermann@ukaachen.de
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unless otherwise stated.the transmission of specific gene expression patterns from
one cell generation to another, ensuring the maintenance
of cellular identity.
So far, more than 60 human genes have been shown to
be imprinted, but there are probably many more (for re-
view: [2]). The normal imprinting marks are inherited
from the parental gametes and are then maintained in
the somatic cells of an individual. Their programming is
subject to an imprinting cycle during life which leads to
a reprogramming at each generation (for review: [3]): In
early development, methylation of the mammalian gen-
ome is comprehensively remodelled, but imprinting marks
are exempt from developmental reprogramming; instead,
they are erased in the germ line and re-established accord-
ing to the sex of the contributing parent for the next gen-
eration. Many genes regulated by genomic imprinting are
found in clusters, that is, imprinted loci often comprise
multiple genes under coordinated control. At the molecu-
lar level, the expression of genes within imprinted regionsntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The four molecular mechanisms of IDs, resulting in a disturbed expression of imprinted genes.
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changes in chromatin structure and by post-translational
histone modifications, collectively designated as epigenetic
regulation (for review: [4,5]).
The epigenetic machinery is extremely complex and
results in a unique transcriptional activity of different
cells with identical DNA sequences. Indeed, this carefully
orchestrated interplay is prone to various disturbances
resulting in distinct pathological courses, for example, ma-
lignant tumours or - in the case of parentally imprinted
genes - IDs. In IDs, the regulation of imprinted genes
can be disturbed by four different molecular alterations:
genomic imbalances (duplications/deletions), uniparental
disomy (UPD; the inheritance of both homologos of a
chromosomal pair from only one parent), epimutations
(disturbed methylation) or point mutations in an imprinted
gene. Whereas in the majority of ID patients, only the
disease-specific loci are affected, an increasing number of
ID patients are reported showing a disturbed methylation
at multiple differentially methylated regions (DMRs), the
so-called multilocus imprinting disturbances (MLID) (see
below). The extreme examples of unbalanced imprinting
patterns are genome-wide UPDs, that is, the whole gen-
ome is inherited only from the father or from the mother.In both cases, the resulting conception is not viable. How-
ever, mosaic genome-wide UPD has been reported to be
compatible with life (for review: [6]).
The known imprinting disorders
Most patients with one of the currently established IDs
are diagnosed in early childhood. In contrast, the diag-
nosis in the prenatal workup or puberty or adulthood
is often hampered because the clinical spectrum is
broad, and some features are subtle, overlapping and
transient. As a result, some IDs are probably mis- and
underdiagnosed.
Each ID is characterised by specific clinical features, and
as they appeared to be associated with specific imprinting
defects, they have been regarded as separate entities. In-
deed, the majority of IDs have some shared clinical char-
acteristics (Table 1), that is:
– prenatal and/or postnatal growth retardation or
prenatal and postnatal overgrowth;
– hypo- or hyperglycemia;
– abnormal feeding behaviour in early childhood and
later; and
– behavioural difficulties in childhood.
Table 1 Overview on the clinical and molecular characteristics of the currently known eight IDslocalization
Imprinting
disorder
Alternative
name/acronym
Frequency OMIM Chromosomesa/
imprinted regions
Type of mutation/epimutation MLID Detection rate Main clinical features
Transient neonatal
diabetes mellitus
TNDM 1/300,000 601410 6q24a: ZAC1/HYMA1 upd(6)pat 40% IUGR, transient diabetes,
hyperglycemia without ketoacidosis,
macroglossia, omphalocelePaternal duplications 40%
Methylation defects Approximately 50% 20%
Silver-Russell
syndrome
Russell-Silver
syndrome, SRS, RSS
1/75,000-
1/100,000
180860 7a upd(7)mat One caseb Approximately10% IUGR/PNGR, rel. macrocephaly,
hemihypotrophy, triangular face,
feeding difficulties11p15
a: upd(11p15)mat Single cases
Maternal duplication <1%
IGF2/H19 Hypomethylation 7% to 10% >38%
CDKN1C Point mutations One family reported
Beckwith-Wiedemann
syndrome
Wiedemann-Beckwith
syndrome, EMG
syndrome, BWS
1/15,000 130650 11p15a: upd(11p15)pat Approximately 20% Prenatal and postnatal overgrowth,
organomegaly, macroglossia,
omphalocele, neonatal
hypoglycemia, hemihypertrophy,
increased tumour risk
Chromosomal aberrations 2% to 4%
ICR1: IGF2/H19; Hypermethylation 5% to 10%
ICR2:KCNQ1 Hypomethylation Approximately 25% 40% to 50%
CDKN1C Point mutations 5% (sporadic) 40%
to 50% (families)
Kagami-Ogata
syndrome
KOS14, upd(14)pat
syndrome
Not known 608149 14q32a: DLK1/GTL2 upd(14)pat Not yet reported ? IUGR, polyhydramnion, abdominal
and thoracal wall defects,
bell-shaped thorax, coat-hanger ribsAberrant methylation
Temple syndrome TS14, upd(14)mat
syndrome
Not known 14q32a: DLK1/GTL2 upd(14)mat One caseb ? IUGR/PNGR, Hypotonia, feeding
difficulties in infancy, truncal
obesity, scoliosis, precocious
puberty
Paternal deletion
Aberrant methylation
Prader-Willi syndrome Prader-Labhart-Willi-
syndrome, PWS
1/25,000 176270 15q11-q13a Paternal deletion One case with PWS
and BWS features
70% PNGR, mental retardation, neonatal
hypotonia, hypogenitalism,
hypopigmentation, obesity/
hyperphagia
-1/10,000 upd(15)mat <30%
Aberrant methylation Approximately 1%
Angelman syndrome Happy puppet
syndrome, AS
1/20,000 105830 15q11-q13a: Maternal deletion Not yet reported 70% Mental retardation, microcephaly,
no speech, unmotivated laughing,
ataxia, seizures, scoliosis-1/12,000 upd(15)pat 1% to 3%
Aberrant methylation Approximately 4%
UBE3A Point mutations 10% to 15%
Pseudohypo-
parathyroidism
PHP1B, PHP1C and
PHP1A
Not known 603233 20q13a Maternally inherited deletions Not yet reported Resistance to PTH and other
hormones
612462 GNAS Causing aberrant methylation Albright hereditary osteodystrophy
103580 Isolated epimutations 12.5% Subcutaneous ossifications
upd(20)pat Feeding behaviour anomalies
Maternal and paternal heterozygous
loss of function mutations in the
coding sequence of GNAS
Abnormal growth patterns
As listed in the second column, for several IDs, different names have been proposed. To reach a consensus on a common nomenclature of IDs, EUCID.net has decided to use the disorders names listed on the left
(see www.imprinting-disorders.eu). IUGR, intrauterine growth retardation; PNGR, postnatal growth retardation. aChromosomes. bCase [27] carries both upd(7)mat and an TS14 epimutations.
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Transient neonatal diabetes mellitus (TNDM) is a rare
disease, characterised as its name implies by transient
hyperglycaemia. In addition, IUGR, macroglossia and ab-
dominal wall defects are common. Insulin therapy is
required for an average of 3 months; afterwards, the
diabetes resolves, but later in life, the majority of TNDM
patients develop type 2 diabetes. TNDM is associated with
an overexpression of PLAGL1/ZAC in 6q24, a maternally
imprinted gene. It encodes a zinc-finger protein which
binds DNA and hence influences the expression of other
genes (for review: [7,8]).
Silver-Russell syndrome
Silver-Russell syndrome (SRS) is mainly characterised by
prenatal and postnatal growth restriction with relative
macrocephaly at birth, severe feeding difficulties during
early childhood and typical facial gestalt and, in many
cases, asymmetry. The genetic basis of SRS is heteroge-
neous. In approximately 10% of SRS patients, a maternal
UPD for chromosome 7 [upd(7)mat] can be found (for
review: [9,10]). More than 40% of SRS patients show a
hypomethylation of the ICR1 DMR in the imprinted re-
gion 11p15. In single cases, genomic alterations in 11p15
chromosomal region have been reported (for example,
maternal duplications). Additionally, numerous (sub-
microscopic) disturbances of other chromosomes than
7 and 11 have been described in SRS patients; thus,
screening for cryptic genomic imbalances is indicated
after exclusion of upd(7)mat and 11p15 epimutations
[11,12]. Furthermore, there is an overlap with Temple syn-
drome (upd(14)mat). The genes causing the SRS pheno-
type on chromosomes 7 and 11 are currently unknown,
but a role of IGF2 and CDKN1C in 11p15 has been
suggested.
Beckwith-Wiedemann syndrome
Beckwith-Wiedemann syndrome (BWS) was initially
called EMG syndrome from its three main features of
exomphalos, macroglossia and (neonatal) gigantism. In
5% to 7% of children, embryonal tumours (most com-
monly Wilms tumour) are diagnosed. The clinical diagno-
sis of BWS is often difficult due to its variable presentation
and the phenotypic overlap with other overgrowth syn-
dromes (for review: [13,14]). In nearly 70% of BWS pa-
tients, an altered expression or mutations of several loci in
11p15 can be observed (including the ICR1 and ICR2
DMRs). ICR2 hypomethylation account for about 50% of
the cases, upd(11p15)pat is the second most frequent mo-
lecular aberration, while ICR1 hypermethylation is less
frequent (2% to 7%). Most BWS cases are sporadic, but
familial inheritance is observed in 15% of all cases.
Microdeletions/duplications or point mutations at the
ICRs are usually found in familial BWS with aberrant11p15 methylation, while CDKN1C mutations are fre-
quent in familial cases with normal 11p15 methylation
[15,16]. These BWS pedigrees resemble that of an auto-
somal dominant inheritance but with incomplete pene-
trance depending on the sex of the inheriting parent. A
genotype/epigenotype-phenotype correlation has re-
cently been established for BWS [17]: hemihypertrophy is
strongly associated with upd(11)pat, exomphalos with
ICR2 hypomethylation and CDKN1C mutations, and, most
importantly, the risk of Wilms tumour is significantly
higher in ICR1 hypermethylation and upd(11)pat than in
the other molecular subgroups. In BWS, the determin-
ation of the molecular subtype is therefore important for
an individual prognosis and therapy. Nevertheless, the
phenotypic transitions are fluid, and testing for all mo-
lecular subtypes should be offered in patients with BWS
features.
Temple syndrome (TS14) [upd(14)mat]) and Kagami-Ogata
syndrome (KOS14) [upd(14)pat]
TS14 (upd(14)mat and WGS (upd(14)pat) were described
in 1991 by Temple et al. and Wang et al. [18,19], re-
spectively. However, the frequencies of both syndromes
are currently unknown. Both IDs were first detected in pa-
tients carrying balanced Robertsonian translocations. Con-
sidering the most important formation mechanism of
UPD via trisomy rescue, this observation was consequent
because Robertsonian translocations are prone to trisomic
offspring. More recently, several cases have been described
with microdeletions affecting 14q32 or with isolated
methylation anomalies affecting the imprinting control re-
gion [20,21].
Among other clinical signs, TS14 is characterised by
prenatal and postnatal growth retardation, muscular hypo-
tonia, feeding difficulties in early childhood, truncal obes-
ity and early onset of puberty. TS14 patients show clinical
features overlapping with PWS and SRS, and thus, screen-
ing for chromosome 14q32 should be performed in pa-
tients with PWS- and SRS-like phenotypes after exclusion
of the specific (epi)mutations.
KOS14 is associated with polyhydramnios, a characteris-
tic small, bell-shaped thorax, abdominal wall defects and a
severe developmental delay. Many patients have been re-
ported to die in utero or in the first months of life, but ex-
ceptions exist.
For both syndromes, the role of an altered RTL1 and
DLK1 expression has been suggested [21].
Angelman and Prader-Willi syndromes
Both Angelman syndrome (AS) and Prader-Willi syndrome
(PWS) are caused by (epi)mutations in 15q11-q13. The
lack of the paternal contribution of this region results in
PWS, while lack of the maternal contribution leads to AS.
Both AS and PWS patients are mentally retarded, but the
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characterised by neonatal hypotonia and failure to thrive
in infancy, with subsequent development of hyperphagia
and obesity (for review: [22]). Approximately 70% of indi-
viduals with PWS have an interstitial deletion of the pater-
nal 15q11-q13 allele, 20% to 30% have maternal UPD of
15q11-q13 while <1% have an imprinting defect (either
primary or secondary). As mentioned before, analysis for
TS14 should be considered in PWS patients without
chromosome 15 disturbances.
AS patients exhibit microcephaly, ataxia, seizures, ab-
sence of speech and sleep disorder (for review: [23]). De-
letion of the maternal copy of 15q11-q13 is observed in
approximately 70% of individuals with AS, paternal UPD
in 7% to 10%, while 3% have an imprinting defect (either
primary or secondary). Around 10% have mutations in
UBE3A.
Due to the high percentage of microdeletions in 15q11-
q13 in both syndromes, AS and PWS also belong to the
so-called microdeletion syndromes, a group of congenital
disorders caused by a chromosomal deletion spanning
several genes but too small to be detected by conventional
cytogenetic.
Pseudohypoparathyroidism
Pseudohypoparathyroidism (PHP) is a group of disorders
united by parathyroid hormone (PTH) resistance in the
kidney, that is, pseudohypoparathyroidism. Most cases of
PHP belong to the type 1, that is, are caused by genetic or
epigenetic alterations at the imprinted GNAS locus. PHP1A
comprises patients affected with resistance to PTH and
thyroid stimulating hormone (TSH) and features of obesity
and Albright’s hereditary osteodystrophy including short
stature, brachydactyly, ectopic ossifications and mental re-
tardation. PHP1A is due to loss of function mutations in
the maternal allele of the GNAS gene. Paternal GNAS mu-
tations are associated with AHO, no hormonal resistance
and no obesity. In contrast, the phenotype of most PHP1B
patients is limited to renal PTH resistance and in some
cases, mild TSH resistance. Few patients with PHP1B dis-
play some features of Albright’s hereditary osteodystrophy.
Patients with PHP1B share a loss of methylation at the
A/B DMR of GNAS, likely leading to the downregulated
expression of the GNAS-Gsa transcript in imprinted tis-
sues. Some patients carry additional epigenomic changes
along the GNAS locus. About 20% of PHP1B are inherited
and due to deletions of GNAS imprinting control regions.
The remaining 80% are sporadic. A small subset is due to
paternal UPD of chromosome 20q, yet the vast majority
are still of unknown cause. While obesity and short stature
are long known features of PHP1A, it became only re-
cently apparent that growth and metabolism are affected
in both paternal and maternal epi/genetic alterations of
the GNAS locus (for review: [24,25]).Molecular alterations in IDs
In nearly all known IDs, the same classes of molecular
changes are detectable. Broadly, the several mechanisms
have an underlying genetic lesion, but a considerable num-
ber have no identifiable genetic cause, and are reproduct-
ive, stochastic or epigenetic in origin (Figure 1).
The genetic lesions include:
a) chromosomal deletions, duplications and
rearrangements;
b) intragenic mutations in imprinted genes.
In familial cases of these genetically caused IDs, parent of
origin dependence of expression results in apparent non-
Mendelian inheritance.
The non-genetic causes consist of:
c) UPD (that is, the inheritance of both chromosomal
homologos from the same parent);
d) epimutations (that is, aberrant methylation without
alteration of the genomic DNA sequence).
It is noteworthy that non-genetic aberrations may
occur post-zygotically, resulting in a mosaic distribution.
Mosaicism can obscure genotype-phenotype correlation,
and is also associated with somatic asymmetry, and dis-
cordant monozygotic twinning.
For genetic counselling of ID families, the knowledge
of the nature of the mutation or epimutation subtype is
essential to delineate exact risk figures. Whereas the recur-
rence risk is generally low in the case of epimutations and
UPD, patients/carriers with submicroscopic deletions or du-
plications might have a 50% risk of conceiving a child with
an ID, depending on the sex of the contributing patient.
However, in each case, genetic professionals are advised to
continually update their knowledge for each disease.
Each of the currently known IDs was initially reported to
be associated with molecular alterations at specific chromo-
somal loci. They have therefore been regarded as separate
entities, but - as mentioned before - with the growing data
on IDs, it becomes apparent that they share both genetic
properties and clinical features. This can cause uncertainty
determining which molecular tests to perform and with what
priority, particularly for patients with growth restriction.
Moreover, the clinical overlap between the different IDs is
reflected on molecular level by the identification of similar
multilocus methylation defects in different phenotypes. In
particular, in growth retarded patients, it is sometimes dif-
ficult to decide which ID-specific test should be applied.
Multilocus imprinting disturbances, a common finding in IDs
The correlation between aberrations at specific imprinted
genes and distinct congenital disorders was generally ac-
cepted for nearly 20 years, but there are growing numbers
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patterns (MLID) (Table 1) (for review: [26]). These patients
often exhibit a specific ID phenotype, for example, BWS,
but molecular testing reveals that aberrant methylation
does not affect only the disease-specific imprinted loci (for
example, 11p15 in BWS) but also other imprinted regions.
Remarkably, patients with opposite phenotypes like BWS
(overgrowth) and SRS (growth retardation) can share
some aberrant methylation patterns in lymphocytes
(lymphocyte DNA is the most frequently and often the
only analysed tissue), and to add a layer of complexity, epi-
genotype anomalies can vary for the same individual depend-
ing on the studied tissue. This has been so far investigated in
SRS patients with 11p15 ICR1 LOM identified initially in
leukocytes. Another example is the phenotype of an upd
(7q)mat carrier with hypomethylation in 14q32 who was
initially diagnosed as SRS (typical for upd(7q)mat but then
exhibited a phenotype suggestive for TS14 [27].
In summary, the clinical picture in patients with methy-
lation aberrations affecting more than one imprinted locus
can be different from that of patients with single epimuta-
tions, but is not necessarily so. As a result, both patients
with typical ID phenotypes as well as those with unusual
clinical features should be tested for MLID.
Two genetic mechanisms causing aberrant methylation
at imprinted loci have been identified: cis- and trans-acting
alterations. Cis-acting alterations affect DNA sequences
which are physically localised adjacent to a structural gene
or its control regions and interact with them. Examples for
cis-acting mutations are rare deletions of CTCF-binding
sites and mutations affecting the OCT- and SOX-binding
elements in 11p15 which mediate the regulation of ICR1:
such mutations affect up to 20% of BWS patients with
11p15 ICR1 GOM [28], but the BWS phenotype is expressed
only if the mutation affects the maternal chromosome 11
[29,30]. Trans-acting factors also influence the expression
of genes, but they act by intermediary diffusible molecules
(proteins, RNAs). Their genes can be localised on the
same chromosome as the target gene or elsewhere in the
genome. Several trans-acting factors have been postulated
to cause MLID (for review: [26]), and indeed, DNA muta-
tions in factors involved in the imprinting cycle have been
reported [31-33].
In addition to these monogenic causes of aberrant im-
printing, the identification of patients with MLID cor-
roborates the hypothesis of an ‘imprinted gene network’,
that is, a network of interacting imprinted genes and re-
gions [34]. By this network, the disturbance of one
member alters the regular expression of the others.
The COST Action BM1208: EUCID.net - a network of
European groups working in the field of IDs
Despite their common underlying (epi)genetic aetiologies,
IDs are usually studied separately by small groups workingin isolation, and the basic pathogenesis and long-term
clinical consequences of IDs remain largely unknown. Ef-
forts to elucidate the aetiology of IDs are currently frag-
mented across Europe, and standardisation of diagnostic
and clinical management is lacking.
To overcome this fragmentation and to achieve a consen-
sus in diagnostic and treatment of IDs, European groups
working on IDs and epigenetic regulation have established
a network, called EUCID.net (European network for human
congenital imprinting disorders; www.imprinting-disorders.
eu), which, for the first time, draws together researchers of
all eight known human IDs in an interdisciplinary activity,
working to advance understanding of the pathophysiology
with the major aim of translating this knowledge to im-
provement of diagnostic and clinical management for
the benefit of the patients and their families. The Action
will harmonise a common system for clinical and molecu-
lar classification as well as nomenclature of IDs, develop
guidelines for treatment through consensus, create stand-
ard operating procedures (SOPs) for diagnosis based on
best current practice, coordinate databases held in differ-
ent countries to make them compatible and useful as a
springboard for collective research initiatives, identify new
imprinting disorders through collaborative effort, educate
researchers and stimulate translational exchange. These
networking activities have become possible with fund-
ing of COST, the European Cooperation in Science and
Technology, (COST Action BM1208).
Objectives of EUCID.net
The objectives of the network will be realised in five
working groups (WGs) described below. The activities
will run in three interdependent directions: (a) Clinical
experts are undertaking the challenging task of standard-
isation and harmonisation of clinical phenotyping and
medical management of IDs, providing guidelines for
IDs’ clinical assessment and management across Europe.
(b) Experts in molecular diagnosis are undertaking the
standardisation of molecular diagnosis of IDs and devel-
opment of consistent reproducible molecular testing. (c)
A coordinated European infrastructure of data sharing
(clinical and molecular data) and samples for genetic and
epigenetic study of IDs will be created (with the possibility
to link clinical, genetic and epigenetic data). This will be
an important step towards improving the standard of care
for IDs in Europe and uncovering the genetic/epigenetic
bases of the disorders.
WG1 - European clinical integration
By European wide cooperation and coordination, this WG
will gather Europe-wide experience in the clinical and
metabolic characteristics and management practices of ID
patients to provide a comprehensive clinical review of
IDs. This will enable the development of standardised
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ment of a disease classification enabling future im-
provements in diagnosis. We will also strive for a current
consensus on clinical management guidelines on which to
build as new developments emerge. With the publication
of disease-specific clinical utility cards, the first step has
been undertaken [35-40].
WG2 - molecular biology
This multidisciplinary WG will unify recording of sam-
ples to create a virtual biobank for IDs across Europe,
creating pan-European resources for the study of the
(epi)genetic basis of IDs. The heterogeneity and com-
plexity of IDs demands the availability of large patient
cohorts which has not been available until now. Further-
more, this WG will attempt to unify the types of the bio-
logical material obtained from affected families (DNA,
RNA, transformation of lymphocytes). This will allow the
identification of factors commonly involved in the aeti-
ology of IDs. This WG will focus on activities aiming on
the identification of new genes, cis-acting control elements
and epigenetic trans-acting factors associated with and/or
causing IDs as a prerequisite for an understanding of
pathophysiological mechanisms. Unravelling the cross talk
between known and new ID genes can place these disor-
ders in an (epi)genomic perspective. This WG will coord-
inate genomic, epigenomic, proteomic and transcriptomic
studies by high-throughput assays. By data exchange,
these new findings and techniques will be implemented in
clinical and diagnostic application.
WG3 - molecular diagnostics
WG3 will discuss important technical aspects related to
molecular diagnosis of IDs, aiming to provide a harmo-
nised testing algorithm for IDs. The partners in WG3
will implement innovative diagnostic algorithms by im-
provement of existing ID-specific tests and by develop-
ment of new tests for specific IDs. The diagnostic utility
of these techniques will be validated, and standardised
algorithms will be progressively incorporated into diagnos-
tic regimes through collective experience. Reference panels
and quality control measures will be established in co-
operation with the European Molecular Quality Network
(EMQN). It is expected that most European experts in the
field of IDs are going to participate in this effort and they
will collaborate with experts around the world, thus turn-
ing this COSTAction into a global initiative.
WG4 - capacity building
Being the springboard for new research ideas, this WG
will use the combined experiences of COST members
to initiate new directions and projects in ID research
responding to research calls through the preparation
and submission of grant proposals to European andinternational funding agencies. Furthermore, networking
activities and short-term scientific missions will be orga-
nised to strengthen the interdisciplinary and transnational
activities.
WG5 - dissemination
This WG will design and coordinate outreach meetings
with patient groups and dissemination activities. It will
receive input from the other WGs and channel their sci-
entific efforts into public dissemination. The publication
of new disease classification systems and clinical guide-
lines, together with coordinated diagnostics, will represent
a major objective for delivering individualized therapeutic
management. This WG will promulgate the results, guide-
lines and clinical classifications to physicians, scientists
and patients’ organisations. WG5 will have close links
with national patients’ organisations.
Organisation
At the beginning in May 2013, 25 groups from 11 European
countries have been part of EUCID.net, including academic
groups, SMEs and patients’ organisations. Until July 2014,
additional groups have joined the network, and it cur-
rently includes 45 groups from 22 European countries.
Furthermore, there are close links and exchanges with ex-
perts from Australia, Canada, Japan, South America and
the USA.
Based on the COST rules, the EUCID.net includes the
following partcipants (Figure 2): A Chair and a Vice-
Chair, both elected, who preside over the management
committee (MC). The MC coordinates the key issues of
the Action. It consists of two representatives per participat-
ing country, including the Coordinator and Co-Coordinator
of each WG. It is responsible for the allocation of funds
and oversees for the overall strategy of the network. The
MC manages operations of the WGs, the programme of
international symposia, as well as training and exchange
programmes. The MC fosters the exchange of scientific
knowledge and active collaborators. Due to its smaller
size, the steering committee (SC), consisting of the WG co/
coordinators, represents a more flexible instrument that
allows the close monitoring of the progress of the Action
and acts as a link between the WGs and the different
groups. Under the directions of the MC, the SC is further-
more responsible for the interaction with existing platforms
in Europe and across the world and relevant stakeholders
(for example, IRDiRC, EURORDIS, Orphanet, EMQN,
EUCERD). Each of the five WGs is chaired by a WG leader
(Coordinator) and a co-leader who have been elected by
the MC during the kick-off meeting. Leader and co-leader
are responsible for the coordination, organisation and
supervision of the WG’s meetings. Each WG is constituted
by different teams, but the teams can be involved in differ-
ent WGs. All members of each WG will meet once a year
Figure 2 Structure and activities of the EUCID.net/COST BM1208, all aiming on networking of researchers, clinicians, SMEs and patients
organisation working in the field of IDs.
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scientific knowledge and data. The investigators of each
WG communicate through regular conference calls and
web-based interfaces. All five WGs are interrelated and
interact through the SC. WG 1 is closely related to WG 2
and 3, establishing tools and guidelines for phenotype
characterization. In turn, WG 2 and 3 are connected to
deciphering the molecular basis of IDs and to translate the
achieved knowledge into diagnostic application. Further-
more, they contribute to the ID classification and develop-
ment of clinical guidelines in WG 1. All efforts from WG1
3 support and stimulate the activities in WG 4 to initiate
new directions and projects. WG1 4 support WG 5 in the
promulgation of the data and achieved knowledge, inter
alia by implementation of WG specific information on the
website in a password protected area.
High priority is given to Early Stage Researchers (ESRs)
and Short-Term Scientific Missions (STSMs) for maxi-
mizing the exchange of experience among the partici-
pants as exchanging ideas and knowledge across borderswill lead to more successful projects. The ID training
school is a further central instrument to pursue these
aims.
Conclusions
Imprinting disorders are underdiagnosed, and currently
available diagnostic and management protocols are sub-
optimal. Improvements in the diagnosis and management
of rare diseases are greatly facilitated by international col-
laboration. EUCID.net aims to promote better clinical care
and scientific investigation of imprinting disorders by
establishing a concerted multidisciplinary alliance of clini-
cians, researchers, patients and families. By encompassing
all IDs and establishing a wide ranging, open and collab-
orative network, EUCID will bring together a wide variety
of expertise and interests to engender new collabora-
tions and initiatives. It is very much hoped that epigen-
eticists with an interest in imprinting disorders will wish
to participate in EUCID.net (contact: teggermann@ukaa-
chen.de).
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